to IMGT/mAb-DB
database logo
1417 entries
1234 -IG
7 -TR
47 -FPIA
68 -CPCA
61 -RPI

IMGT/mAb-DB card

Version: 2.0.4 (2023-04-14)

Citing IMGT/mAb-DB

Manso T., Kushwaha A., Abdollahi N., Duroux P., Giudicelli V. and Kossida S. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol., 14 (2023). DOI 10.3389/fimmu.2023.1129323

Poiron C., Wu Y., Ginestoux C., Ehrenmann, Duroux P. and Lefranc M.-P. IMGT/mAb-DB: the IMGT® database for therapeutic monoclonal antibodies. JOBIM 2010, Paper 13 (2010). Abstract PDF

Cambon M., Cherouali K., Kushwaha A., Giudicelli V., Duroux P., Kossida S. and Lefranc M.-P. IMGT/mAb-DB and IMGT/2Dstructure-DB for IMGT standard definition of an antibody: from receptor to amino acid changes. JOBIM 2018, Poster 201 (2018). Abstract PDF

INN gemtuzumab
INN Number 8024
INN Prop. List 83 (2000)
INN Rec. List 45 (2001)
Common name CMA-676 (ADC), hP67.6 (naked), CDP-771, WAY-CMA-676, hP67.6-calicheamicin (ADC),, MYLOTARG® (gemtuzumab ozogamicin)
Proprietary name
Species Humanized
IMGT receptor type IG
Format (legend)
Receptor identification IgG4 - kappa
Radiolabelled / Conjugated / Fused conjugated with N-acetyl-gamma calicheamicin
Specificity target name and species CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67) [Humanized]
Development Technology
Origin clone species Mus musculus
Origin clone name P67.6

Company Pfizer (New York NY USA)
Expression system NS0 mouse myeloma cells
Application Therapeutic
Clinical domain Hematology; Oncology
Mechanism of action
Clinical indication Acute myeloid leukemia (AML) (CD33 positive)
Development status Phase III
Regulatory agency status and year
  • FDA withdrawal (by Pfizer, on concerns about the product's safety and absence of clinical benefit in trials) June 01, 2010
  • FDA approval May 17, 2000

Clinical trials 102 studies found, 31 recruiting
Authority decisions
  • EMA: EMEA/37537/2008 (refusal of the marketing authorisation April 14, 2008)
External links
IMGT citations
  • Information provided by Mitchell Reff, IDEC Pharmaceuticals.
  • Marie-Paule Lefranc, IMGT (26/12/2005).
IMGT notes
  • Calicheamicin is a cytotoxin antitumor antibiotic, isolated from fermentation of a bacterium, Micromonospora echinospora, subsp. calichensis.
  • Pfizer (New York NY USA) acquiered Wyeth Pharmaceuticals (Madison NJ USA) in 2010
  • Although gemtuzumab (#44, INN 8024 (83)(45)) has been used, conjugated with ozogamicin and marketed as MYLOTARG┬«, the INN for 'gemtuzumab ozogamicin' (#649, INN 10315 (115) (77)) has only been published in 2016 (L115). Updates for gemtuzumab ozogamicin posterior to 2016 are reported in the entry #649 gemtuzumab ozogamicin INN number 10315 (115).
    Format legend:

    © Copyright 1995-2023 IMGT®, the international ImMunoGeneTics information system® | Terms of use | About us | Contact us | Citing IMGT
    European Commission umontpellier CNRS